Member Article

Liverpool life sciences promoted in US

Two Liverpool businesses will help to promote the city’s life sciences at a global event for biotechnologies in Boston.

Dr Geoff Wainwright of 2Bio Ltd and Dr Neil Murray of Redx Pharma will represent the city’s sector at the BIO International Convention.

The pair’s presence at the Boston event is supported and part-financed through LCR Local Enterprise Partnership’s European funding.

They will join an expected 25,000 delegates from more than 65 countries as the Convention covers the newest opportunities for executives, investors, scientists and policy leaders from around the world.

Geoff Wainwright said: “Liverpool is a compelling proposition for investment because of our concentration of clinical, medical, educational and research assets.

“We have a unique partnership between our leading organisations, including Redx Pharma, Liverpool Vision, Liverpool City Council, our major teaching hospitals, the new Life Sciences University Technical College and our Universities in order to deliver an exciting new model of development for the life science industry.

“It will connect academic and specialist research assets to emerging technologies that have major market potential which will help propel the city as a leading international centre for life sciences.

“This conference is the most important place in the life sciences calendar to meet key contacts and build the right commercial relationships.”

Dr Neil Murray added: “Biotech is a truly international business and we’re pleased to see Liverpool Vision and the LEP championing the city’s biotechnology assets.

“Liverpool does have an increasingly integrated approach to bringing together the infrastructure, relationships and skills necessary to support the growth of life science companies in the region.

“For Redx, BIO is a key international event that presents us with an important opportunity to meet partners and we are looking forward to pressing Liverpool’s case on the world stage.”

Dr Wainwright and Dr Murray will work closely with Kristen Hirst, Liverpool Vision’s director for It’s Liverpool in the USA, who will build the city’s US bio strategy and follow up on leads from the conference.

Max Steinberg, chief executive of Liverpool Vision, added: “Science and innovation lie at the heart of Liverpool’s strategy for growth.

“Liverpool already has an important Knowledge Quarter which boast a breathtaking and unrivalled combination of knowledge assets which reach out to every corner of the world and every aspect of modern life.

“Our ambition is huge and we are actively looking to secure a 2m sq ft Biocampus, encompassing one of Europe’s biggest clusters of bio-businesses, research facilities and a state of the art new teaching hospital.

“There is a real affinity between our ambition and our approach because Liverpool is a location where entrepreneurial businesses like Redx Pharma can find the right support and conditions to reach their own aspirations.”

This was posted in Bdaily's Members' News section by Tom Keighley .